The overexpression of PD-1 potentiates CD8+ T-cell exhaustion; therefore, anti-PD-1 ICI may stimulate the exacerbation of symptoms in patients with pre-existing MG [40]. The gene discussed is PDCD1; the disease is myasthenia gravis.